Standardizing the Amyloid Frontier: Inside FDA Clearance of MICSI-PET
Dr. Dereck Mush, MD, MBA
What they do
Quibim develops medical software that extracts quantitative imaging biomarkers from MRI, CT, and PET scans. The company's platform helps oncology, neurology, and immunology clinicians and pharmaceutical researchers evaluate disease progression and monitor treatment efficacy through objective tissue analysis.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Quantitative imaging biomarkers
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Valencia, Spain
- Region
- Europe
- Founded
- 2015
- Total funding
- $15M raised
Notable investors: Adara Ventures, Amadeus Capital Partners, Partech, TechTransfer UPV.
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Beyond RECIST 1.1: The AI Endpoint Playbook for Modern Oncology Trials
Dr. Dereck Mush, MD, MBA
Decentralizing the Neuro-ICU: The Clinical Economics of Quantitative Bedside Brain Monitoring
Dr. Dereck Mush, MD, MBA
Point-of-Care Ultrasound Is the Quiet Revolution in Diagnostics
Dr. Dereck Mush, MD, MBA